Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is positioned for success with their diverse pipeline and expertise in protein engineering, with potential for blockbuster success and data releases for their lead program and bispecific antibody in development. Although there are potential risks and exclusions in their current clinical trials, there is still strong investor interest and confidence in the company's potential treatments for IBD and other inflammatory and immune-mediated diseases.

Bears say

Shattuck Labs is facing a negative outlook based on their limited pipeline, with only one candidate in Phase 2 development for Crohn's disease, and their reliance on a single target pathway that is being explored by multiple companies. The high failure rate of treatments for inflammatory diseases, coupled with the competitive landscape, raises concerns about the success of Shattuck Labs' efforts and their potential for financial success in the long run. Additionally, the company's limited pipeline and lack of diversity in its drug development efforts may hinder its ability to pivot and adapt to changes in the market and regulatory landscape.

Shattuck Labs (STTK) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 5 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.